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Abstract 
Traditional wisdom holds that intact immune responses, such as immune surveillance or 
immunoediting, are required for preventing and inhibiting tumor development; but re-
cent evidence has also indicated that unresolved immune responses, such as chronic in-
flammation, can promote the growth and progression of cancer. Within the immune 
system, cytotoxic CD8+ and CD4+ Th1 T cells, along with their characteristically pro-
duced cytokine IFN- function as the major anti-tumor immune effector cells, whereas 
tumor associated macrophages (TAM) or myeloid-derived suppressive cells (MDSC) and 
their derived cytokines IL-6, TNF, IL-1 and IL-23 are generally recognized as dominant 
tumor-promoting forces. However, the roles played by Th17 cells, CD4+ CD25+ Foxp3+ 
regulatory  T  lymphocytes  and  immunoregulatory  cytokines such  as  TGF-  in  tumor 
development and survival remain elusive. These immune cells and the cellular factors 
produced from them, including both immunosuppressive and inflammatory cytokines, 
play dual roles in promoting or discouraging cancer development, and their ultimate role 
in cancer progression may rely heavily on the tumor microenvironment and the events 
leading to initial propagation of carcinogenesis. 
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Introduction 
Cancer cell development and survival is a mul-
tifactor process, involving genetic mutation of normal 
cells  as  well  as  physiological  changes  within  both 
cancer cells and also the body’s defense mechanisms(1, 
2).  Cellular changes, such as gain of function muta-
tions of oncogenes and loss of function mutations in 
tumor suppressor genes, can lead to relative cellular 
immortality, proliferation, and carcinogenesis. In ad-
dition to cellular changes, the body’s normal defense 
mechanisms  can  play  a  key  role  in  encouraging  or 
combating carcinogenesis and tumor spread. Of par-
ticular importance is the immune response to cancer 
cell development and progression, as well as the po-
tential role the immune response might play in initial 
tumor formation. In this regard, compelling evidence 
has been documented, both in animal tumor models 
and  in  human  cancers,  that  chronic  inflammation 
plays  a  decisive  role  in  the  development  of  certain 
cancers such as hepatocellular carcinoma (HCC) and 
colon cancer. However, cells of the immune system 
can  also  inhibit  tumor  growth  and  progression 
through  the  recognition  and  rejection  of  malignant 
cells, a process referred to as immunosurveillance or 
immunoediting (3, 4). In this respect, immunodeficien-
cy can predispose an individual to the development of 
both  spontaneous  and  virally  induced  cancers,  and 
established  tumors  often  generate  immunosuppres-
sive  microenvironments  that  can  block  productive 
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antitumor immunity. Of the plethora of cells, soluble 
factors  and  cytokines  involved,  tumor-associated 
macrophages (TAM) or myeloid-derived suppressive 
cells (MDSC) and their secreted cytokines IL-6, TNF, 
and IL-1 may be key in promoting the progress of 
tumor development. However, the cellular and mo-
lecular  mechanisms  that  positively  and  negatively 
regulate the function and phenotype of TAM remain 
largely  unknown.  Elucidation  of  these  mechanisms 
would have a significant impact on understanding the 
pathogenesis of inflammation-associated cancers, and 
could aid progress in the development of more effec-
tive  cancer  therapies.  This  review  will  explore  the 
dual-roles  played  by  key  T  lymphocyte  subsets  in 
cancer development and progression, as well as dis-
cussing the potential link between TAM cells and T 
lymphocytes  as  they  relate  to  tumor  formation, 
growth and survival.  
Inflammation and cancer  
A causal association between viral infection and 
tumor  development  has  been  well  established  and 
supported in animal studies as well as epidemiologi-
cal studies. For example, the risk of developing HCC 
appears  to  be  intimately  linked  to  the  duration  of 
Hepatitis B and C viral infection-induced inflamma-
tory processes (1, 5-7). Normally, inflammation serves to 
protect a defined region of infected or damaged tissue 
by  recruiting  cells  necessary  to  resolve  the  insult 
while also isolating the area to prevent the spread of 
infection and, once resolved, normal tissue function is 
typically restored. However, inflammation sometimes 
fails to subside and this unresolved inflammation can 
promote tumor cell growth, survival and angiogene-
sis (1). Intriguingly, evidence continues to accumulate 
indicating  that  unresolved  chronic  inflammation 
plays a critical role in the initiation, promotion, ma-
lignant conversion, and metastasis of several human 
cancers  (1).  Additionally,  inflammation  associated 
with the hepatitis B and C viruses is the primary cause 
of liver  cancer.  Infection with  the  bacterium  Helico-
bacter pylori plays a central role in the development of 
most  cancers  of  the  stomach  (8).  Beyond  infections, 
many  autoimmune  diseases  are  associated  with  an 
increased  risk  of  lymphoma, and  inappropriate  im-
mune responses to commensal flora in ulcerative co-
litis  are  strongly  linked  to  colon  cancer  (1,  8-10).  Evi-
dence now links inflammation to tumor development 
in both genetic tumor syndromes and in the context of 
chronic  carcinogen  exposure.  Administration  of 
non-steroidal  anti-inflammatory  drugs  (NSAIDs)  in 
randomized studies have shown reduced incidence of 
colon  cancer  in  patients  with  familial  adenomatous 
polyposis and, perhaps more remarkably, reduces the 
incidence of lung cancer in smokers (10-13). 
Immune cells within the tumor microen-
vironment 
Tumor-associated macrophages and mye-
loid-derived suppressive cells 
Within  the  microenvironment,  TAM  −isolated 
from established metastatic tumors in both mice and 
humans− play a vital role in tumor cell development, 
survival and growth. TAM are a heterogeneous cell 
population according to oxygen availability (hypoxia 
vs.  normoxia)  and  to  tumor  progression  (small  vs. 
advanced tumors)  (14, 15). In early stage tumor devel-
opment Type 1 macrophages (M1) may infiltrate, ac-
tivated in response to inflammatory mediators, and 
release pro-inflammatory cytokines and chemokines, 
such as CXCL19 and CXCL10, in order to attract and 
encourage Th1, Th17 and NK cell development and 
differentiation.  M1  macrophages  are  activated  by 
signals such as bacteria and LPS, however the cellular 
factors  GM-CSF  and  IFN-γ  produced at  sites  of  in-
flammation will also tend to polarize towards the M1 
state. It has been shown that these conditions promote 
IRF5 expression in macrophages, leading to produc-
tion and maintenance of M1 phenotypic markers and 
encouraging lymphocyte proliferation and Th1/Th17 
cellular responses by directly up-regulating the tran-
scription of IL-12p35, IL-12p40, IL-23 and TNF-α (16). 
In contrast, in more advanced tumors or in hypoxic 
regions of the tumor microenvironment TAM polarize 
to  a  more  type  2  macrophage  (M2)  related  cell,  re-
leasing factors to encourage Th2 differentiation and 
recruitment (15). M2-like TAM express a distinct set of 
cytokines and chemokines including CCL17, CCL22 
and CCL24 favoring regulatory T cell (Treg) recruit-
ment and development. Moreover, M2 macrophages 
support tissue repair and remodeling, as well as an-
giogenesis through the production of VEGF or EGF 
(14). Overall, these TAM cells can be pro-inflammatory 
with  M1-type  cells  promoting  cell  growth  and  re-
cruitment through the production of chemokines and 
cytokines such as IL-6, TNF-α, IL-23 and IL-12 (1, 5, 17, 
18), and may also serve to promote tumor development 
and immunoregulation with M2-like TAM inhibiting 
anti-cancer  immunity  through  the  production  of 
transforming growth factor β1 (TGF-β) and IL-10 (14, 18, 
19).  
Myeloid-derived  suppressive  cells  represent  a 
heterogeneous population of immature myeloid cells 
not  already  committed  into  macrophages,  dendritic 
cells or granulocytes. These MDSC exert suppressive 
functions, regulating T cell responses through nitric Int. J. Biol. Sci. 2011, 7 
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oxide,  reactive  oxygen  species  and  TGF-β  secretion 
while  also  promoting  Treg  induction  and  favoring 
anti-inflammatory  responses  (19,  20).  These  cells  are 
found within both human and mouse tumors. MDSC 
produce high levels of IL-6 and are responsive to IL-6 
but  also  IL-1β  and  IFN-γ.  Moreover,  expansion  of 
MDSC  in  response  to  macrophage-derived  factors, 
such  as  VEGF,  has  been  reported  (19,  20).  Whereas 
MDSC would normally differentiate after migration, 
the  cytokines  and  cellular  factors  found  within  the 
tumor microenvironment prevent differentiation and 
instead  encourage  expansion  and  activation  of  the 
immature myeloid cell population (19), and may result 
in the suppression of tumor immunity through a va-
riety of mechanisms.  
IL-6  is  a  key  cytokine  amongst  these  cellular 
factors,  encouraging  cancer  cell  proliferation  while 
also inhibiting their apoptosis through activation of 
signal  transducer  and  activator  of  transcription  3 
(Stat3)  (1,  21). IL-6 signaling can also influence T cell 
subset differentiation, particularly in the presence of 
other cytokines such as TGF-β (22). IL-6 has also been 
shown to play an important role in carcinogen-driven 
liver cancer development (7, 23). Additionally, IL-6 acts 
as an angiogenic factor, and has been implicated in 
many of the same processes as TNF. TNF itself also 
plays an essential role in several models of cancer, and 
is a critical inflammatory mediator in many autoim-
mune  diseases  of  both  mice  and  humans  primarily 
acting via induction of NF-κB  (5, 6). TNF plays an in-
dispensible role in the hepatic procarcinogen diethyl-
nitrosamine-induced  experimental  hepatocellular 
carcinoma, as ablation of TNF receptor I in mice al-
most  completely  abolished  obesity-enhanced  HCC 
development (7). IL-1β can activate NF-κB in a manner 
similar  to  TNF,  and  polymorphisms  in  IL-1β  have 
been linked to gastric cancers (24). Notably, during the 
cross-talk  between  cancer  and  inflammatory  cells, 
Stat3 and NF-κB seem to be key transcription factors 
linking a mutual positive feedback loop and promot-
ing cancer progression (5, 21). In an experimental model 
of  Src  oncogene-dependent  cancer  transformation, 
induction of inflammation was critical for oncogenesis 
and  Src-induced  inflammation  was  mediated  by 
NF-κB  leading  to  increased  IL-6  production,  which 
then in turn increased Stat3 activation. The IL-6 in this 
tumor model served to further activate NF-κB, caus-
ing  a  positive  feedback  loop  of  inflammation  and 
tumorigenesis (25). 
CD4
+ Th1 and CD8
+ T cells 
It is generally recognized that IFN-γ producing 
CD4+ Th1 cells and CD8+ T cells play an important 
role in inhibiting and killing tumor cells and imped-
ing  tumor  growth.  Spontaneous  lymphocytic  infil-
trates  can  be  consistently  observed  in  a  variety  of 
human cancers, and in some cases these infiltrating 
lymphocytes correlate with a favorable prognosis  (3). 
Anti-tumor  specific  effector  immune  cells  develop 
within the draining lymph nodes, but have also been 
found to proliferate within the tumor microenviron-
ment  despite  potential  immunosuppressive  factors 
(26), however the extent to which these cells are able to 
contribute to anti-cancer immunity is unclear; partic-
ularly with respect to the immunosuppressive condi-
tions present within the tumor. Amongst the many 
factors Th1 and CD8+ T cells produce, IFN-γ seems to 
be one of most significant cytokines preventing and 
suppressing the development of cancers. In addition, 
the cytotoxic effects of CD8+ T cells may also directly 
mediate  the  death  of  tumor  cells.  Given  the  recog-
nized tumor promoting function of macrophages and 
their inflammatory cytokines, the potential effects of 
these  anti-tumor  immune  Th1  and  CD8+  T  cells  on 
TAM over the course of HCC tumor development and 
progression are desperately needed.  
CD4
+ CD25
+ Foxp3
+ regulatory T cells 
Not all T cells are anti-tumor effector immune 
cells;  a  subpopulation  of  CD4+  T  cells  expressing 
CD25  and  the  master  transcription  factor  Foxp3 
(CD4+CD25+Foxp3+),  termed  regulatory  T  cells 
(Tregs), play a role in promoting tumor growth and 
progress by inhibiting the immune response against 
cancer  (27-29).  A  critical  function  of  these  cells  is  to 
suppress the activation of effector immune cells that 
are specific for self-antigens, limiting autoimmunity 
and inflammation under physiologically normal con-
ditions. Loss of function mutations of the Foxp3 gene 
in both mice and humans results in fatal autoimmun-
ity affecting multiple organ systems, and depletion of 
the  Foxp3+  Treg  population  in adult mice  was also 
found to result in severe and fatal full-body autoim-
munity (30-32). Tregs inhibit the activation of both CD4+ 
and CD8+ T cells, and within the tumor microenvi-
ronment may serve to suppress anti-cancer cell im-
munity. Studies of murine tumors indicate that Tregs 
inhibit the immune response to tumors, and depletion 
of  these  cells  promotes  rejection  of  several  murine 
tumor  cell  lines  including  melanoma,  fibrosarcoma, 
leukemia  and  myeloma.  In  some  murine  tumors 
(melanoma and fibrosarcoma), both CD4+ and CD8+ T 
cells were found to be required for tumor rejection, 
while only CD8+ T cells were required for the rejection 
of murine myeloma (33). The role of Tregs in carcino-
genesis and metastasis in humans is just beginning to 
emerge. In pancreatic and breast cancer patients, the 
prevalence of CD25+ regulatory T cells in the blood Int. J. Biol. Sci. 2011, 7 
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has been shown to be much higher than that found in 
normal  donors.  In  cervical  and  endometrial  cancer 
patients,  functioning  CD25+  regulatory  T  cells  have 
been  identified  within  the  tumor  draining  lymph 
nodes.  In  non-small  cell  lung  cancer  and  ovarian 
cancer, tumor associated T cells contained increased 
proportions of  CD25+  regulatory  T  cells and  it  was 
further  shown  that  these  cells  secrete  the  immuno-
suppressive  cytokine  TGF-  (34).  The  role  of  TGF- 
mediated immunosuppression by CD25+ regulatory T 
cells in colorectal cancer has also been documented 
(35). The role of Tregs in the development of liver car-
cinomas, however, remains largely unknown. It has 
been  reported  that  in  both  experimental  murine 
models and human patients with HCC, the frequency 
of CD4+ Foxp3+ Tregs was increased (36). However, the 
impact of Tregs in the development of HCC, initiated 
by TAM-mediated inflammation, remains elusive. In 
particular,  whether  and  how  CD4+  Tregs  affect  the 
behavior  and  function  of  TAM  is  unknown.  Con-
versely, it is also unclear how TAM and TGF- regu-
late the generation and function of Tregs in the de-
veloping and established solid tumor microenviron-
ment.  
Contrasted  with  the  possible  tumor-promoting 
role  of  these  cells  in  the  progression  of  established 
tumors, the role of CD4+ Foxp3+ Tregs in initial tumor 
transformation  caused  by  chronic  inflammation  re-
mains elusive. Based on the potent immunoregulatory 
function these cells have on immune responses and 
inflammation, it is reasonable to conceive that Tregs 
may  in  fact  help  prevent  and/or  delay  inflamma-
tion-mediated tumor development. In this regard, the 
CD4+  Tregs  in  the  gut  may  prevent  chronic  coli-
tis-triggered colon cancer by inhibiting inflammation 
within the colon. However, the experimental evidence 
supporting this notion awaits further investigation.  
Th17 cells 
Similar  to  Tregs,  the  role  of  IL-17  producing 
CD4+ cells (Th17) in the growth, survival, and pro-
gression of HCC also remain unknown. Th17 cells are 
involved in several autoimmune diseases and chronic 
inflammatory syndromes. Naive CD4+ T cells prefer-
entially  differentiate  into  the  Th17  T  cell  subset  in 
response to the combined signals of TGF-β and IL-6, 
mediated through Stat3 activation. In addition, IL-23 
is a key factor for maintaining and expanding Th17 
inflammatory  cell  populations  (37).  IL-23  is  another 
recently  identified  pro-carcinogenic  cytokine,  pro-
moting  inflammation  and  angiogenesis  within  the 
tumor microenvironment while reducing CD8+ T cell 
infiltration (38). The presence of these Th17 cells within 
the  tumor  microenvironment  could  antagonize  and 
counter the tumor-suppressive IFN-γ producing CD4+ 
Th1 cells (22, 24). In addition, a study of murine tumor 
formation, using the B16 melanoma cell line, found 
that IL-17 signaling was critical for tumor develop-
ment, with direct effects on tumor and stromal cells 
inducing IL-6 production which then led to activation 
of Stat3  (39). Th17 cells antagonize the differentiation 
and function of IFN- producing Th1 cells, and are 
thereby  likely  involved  the  promotion  of  tumor 
growth.  However,  another  study  found  a  potential 
anti-tumor  role  for  adoptively  transferred  tu-
mor-specific Th17 cells by promoting tumor-specific 
CD8+ T cell activation in a model of lung melanoma in 
IL-17A deficient mice (40). Since HCC cells, TAM and 
MDSC are able to produce large amounts of IL-6 and 
TGF-β, it is tempting to envision that Th17 cells could 
be preferentially differentiated in the tumor microen-
vironment of HCC, particularly in established tumor 
tissues.  Thus,  the  combined  cellular  products  from 
both  Th17  and  myeloid  cells  infiltrating  the  tumor, 
and the interaction between these cell types, may play 
a critical role in the balance of anti- and pro-tumor 
immune  responses  within  the  HCC  microenviron-
ment.  
Immunosuppressive cytokines within the 
tumor microenvironment 
TGF- 
As mentioned, TAM also produce immunosup-
pressive  cytokines  that  inhibit  anti-tumor  immune 
cells such as CD8+ and Th1 cells in established cancer 
tissues, further facilitating cancer progression. TGF- 
and IL-10 are two such immunoregulatory cytokines 
identified and produced within the tumor microen-
vironment.  TGF-  plays  an  indispensible,  yet  com-
plex,  role  in  carcinogenesis  and  the  progression  of 
tumors  (41, 42). With regard to immune cells, it is rec-
ognized that TGF- is largely an immunosuppressive 
cytokine, generally inhibiting immune responses in-
cluding  anti-cancer  immunity.  In  addition,  TGF- 
plays a central role in the generation and function of 
CD4+ CD25+ Tregs (27). However, the ultimate effect of 
TGF-β on immune cells is heavily dependent on the 
microenvironment  and  the  presence  of  other  cyto-
kines and factors (43). For example, TGF- suppresses 
IFN- production by Th1 and CD8+ T cells while also 
promoting  the  generation  of  Foxp3+  Tregs  and  dif-
ferentiation of Th17 cells, which, when taken together, 
likely favors the growth and progression of cancer. 
However, TGF- is also a potent inhibitor of macro-
phage  activation  and  decreases  their  production  of 
inflammatory cytokines such as IL-6, TNF and IL-1β, 
which  may  impede  inflammation-associated  cancer Int. J. Biol. Sci. 2011, 7 
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development.  It  will  be  critical  to  understand  what 
role, if any, TGF-has at the interface between T cells and 
macrophages within the tumor microenvironment. 
IL-10 
IL-10 may play a similarly complex role in the 
development and survival of cancer cells. It has been 
shown that IL-10 production from CD25+ Tregs aids 
in regulating immune responses, and, in certain cases 
of  chronic  infection,  IL-10  is  essential  for  proper 
downregulation  of  inflammation  and  prevention  of 
eventual  carcinogenesis  in  microbial-induced  colitis 
mice models  (44-46). IL-10 can also inhibit NF-κB acti-
vation and may hinder angiogenesis within the tumor 
microenvironment. Despite this, however, IL-10 can 
also activate STAT3 and may thereby help to promote 
tumor development, playing a part in cell prolifera-
tion  and  survival  (24,  47).  The  role  of  IL-10 in  cancer 
development being either primarily anti-tumor, pre-
venting  inflammation  and  tumor  angiogenesis,  or 
primarily  pro-tumor,  encouraging  cell  survival  and 
suppressing  effector  T  cells,  may  depend  upon  the 
conditions  of  initial  carcinogenesis  as  well  as  the 
presence of other cells such as Tregs. 
Concluding Remarks 
Accumulated  evidence  has  indicated  that 
chronic  and  unresolved  inflammation  may  play  a 
critical  role  in  the  initiation,  development,  growth, 
and metastasis of cancer. The net outcome of the battle 
between  the  anti-tumor  and  the  tumor  promoting 
immune  cells  and  their  associated  cytokines  within 
the  tumor  environment  will  determine  the  ultimate 
fate of the affected tumors. Thus, understanding the 
interactions and mutual regulation of these complex 
immune  networks  within  the  tumor  environment, 
rather  than  the  role  of  individual  components,  is 
much  more  likely  to  guide  us  towards  developing 
effective and specific cancer therapeutics. It is gener-
ally believed that CD4+ Th1 and CD8+ T cells comprise 
the primary force of immune cells responsible for in-
hibiting tumor growth and development, while TAM, 
MDSC, Cd4+Foxp3+Treg cells and Th17 cells and their 
associated  cytokines  IL-6,  TNF,  IL-1β,  IL-23  and 
TGF-β  may  play  important  roles  in  promoting  the 
growth and survival of cancer. However, it is difficult 
to draw a distinction and establish clear “black and 
white” classifications for which cell types are always 
pro-tumor or always anti-tumor.  
Of particularly complexity is the immunoregu-
latory cytokine TGF-. It has been long known that 
most  tumor  cells  produce  large  amounts  of  TGF- 
Macrophages  are  a  major  cellular  source  of  TGF- 
during normal immune system responses. However, 
surprisingly, it is less known whether and how TGF- 
functions in the cross-talk between TAM and cancer 
cells. In terms of the direct relationship between tu-
mor  cells  and  TGF-β,  as  well  as  the  potential  role 
TGF-β plays in determining T cell differentiation fate 
within  developing  and  established  tumors,  many 
outstanding  questions  remain  to  be  answered.  For 
example, what is the effect of TGF- on TAM within 
the  tumor  environment?  Does  TGF-  influence  the 
production of proinflammatory cytokines IL-6, TNF 
and TGF- in TAM? Of further importance is under-
standing whether TGF- production, by either TAM, 
MDSC  or  cancer  cells,  preferentially  induces 
CD4+Foxp3+ regulatory T cells, or instead promotes 
the development of Th17 cells within the microenvi-
ronment of tumors. The ultimate outcome of TGF-’s 
effects on tumor development and survival will most 
probably depend upon the balance of its activity at the 
interface between the cancer cells and the tumor as-
sociated  immune  cells.  Further  research  into  better 
understanding  this  balance  at  all  stages  of  carcino-
genesis is essential for the development of effective 
cancer therapies that target or utilize immunological 
mechanisms.  
A similar paradox exists in determining the role 
of CD4+ Foxp3+ Tregs in tumor development, which is 
further complicated and particularly important given 
the  control  TGF-has  over  Treg  induction.  With 
chronic  infection  or  autoimmunity,  CD4+  Treg  cells 
help to limit inflammation and may hinder carcino-
genesis  by  limiting  cellular  damage  and  inhibiting 
cycles of proliferation. Once a tumor is established, 
however,  Tregs  and  their  produced  cytokines  may 
instead play a role in promoting tumor survival by 
inhibiting cancer cell destruction. It is reasonable to 
assume that effector immune T cells could infiltrate 
into tumors and counter the growth and progression 
of cancer cells. However, to what extent Tregs may 
influence  the  effector  T  cell  population  within  the 
tumor  microenvironment  remains  unclear.  Further 
unknown is what role Th1 and CD8+ T cells have on 
influencing both the local cytokine profile within the 
microenvironment  as  well  as  what  influence  these 
effector T cells have on TAM activity in either devel-
oping or established solid tumors. Given the recog-
nized tumor promoting function of macrophages and 
their inflammatory cytokines, the potential effects of 
these  anti-tumor  immune  Th1  and  CD8+  T  cells  on 
TAM over the course of tumor development are des-
perately needed. 
Our  belief  is  that  the  tumor-associated  macro-
phages and oncogenic inflammation are regulated at 
multiple levels by T cell subsets, immunoregulatory 
cytokines, and also intracellular transcription factors Int. J. Biol. Sci. 2011, 7 
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such as NF-κB and STAT3. The net outcome of these 
complex regulations determines whether or not tumor 
cells grow, recur, and intrude, and thereby have an 
impact on the eventual survival of patients with can-
cer. While Treg cells and their cytokines likely serve to 
promote  cancer  cell  growth  and  survival  in  estab-
lished tumors, these same immunosuppressive prop-
erties  also  prevent  autoimmunity  and  early  stage 
cancer development. Even within established tumors 
immunoregulatory  cytokines,  such  as  TGF-β  and 
IL-10,  play  potentially  opposing  roles  in  both  pro-
moting and discouraging cancer cell survival and a 
more thorough understanding of their effect in rela-
tion to the plethora of other cytokines and immune 
cells within the tumor microenvironment is needed. 
Th17 cells may play a key role in providing a constant 
proinflammatory  environment  within  established 
tumors while also influencing cell fate decisions and 
activation. Chronic infection and inflammation could 
provide the priming to encourage initial carcinogene-
sis,  and,  whilst  establishing,  TAM  and  MDSC  cells 
may  heavily  encourage  Th17  cell  development  and 
proliferation  through  the  production  of  TGF-β  and 
IL-6 cytokines. A proposed model outlining how this 
cycle  of  inflammation  may  perpetuate  and  lead  to 
cancer  development  and  survival  can  be  found  in 
Figure 1.  
 
 
Figure 1. A proposed model of chronic in-
flammation progressing to tumor formation. 
A  chronic  insult  such  as  autoimmunity  or 
infection leads to a steady inflamed tissue 
state. Tumor-associated macrophages (TAM) 
of the M1 variety begin to produce cytokines 
that promote Th17 cell differentiation from 
naïve CD4
+ T lymphocytes such as IL-6, IL-23, 
IL-1β and TNF-α. One of the key cytokines 
produced by M2 TAM is TGF-β, which may 
further  encourage  Th17  development.  My-
eloid-derived suppressor cells serve an im-
munosuppressive  role  within  the  microen-
vironment  by  producing  TGF-β  as  well  as 
other regulatory factors, but may also en-
courage  further  Th17  differentiation  by 
secreting  IL-6.  The  production  of  TGF-β 
would likely also have the effect of inducing 
CD4
+Foxp3
+Tregs  within  the  tumor  micro-
environment  while  also  suppressing  in-
flammatory  cytokine  production  from  the 
TAM themselves. However, these combined 
suppressive signals may not be sufficient to 
overcome  the  self-perpetuating  cycle  of 
activation  established  between  Th17  cells 
and TAM. At the same time, this suppressive 
environment may greatly hamper, or even 
eliminate, the possibility for Th1 and CD8
+ T 
cells to mount an immune response. The net 
effect of these cellular interactions within 
the  tumor  microenvironment  is  to  limit 
anti-tumor  immunity  from  Th1  and  CD8  T 
cells while continuing to encourage chronic 
inflammation,  angiogenesis,  and  overall 
cancer cell survival and proliferation. 
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Once initially established, Th17 cells may then 
create a chronic environment of inflammatory factors 
that  further activates  TAM  and  self-propagates,  en-
couraging  angiogenesis  and  cancer  cell  survival 
through STAT3 activation and anti-apoptotic protein 
production. The immunosuppressive effects of Tregs 
within  the  tumor  microenvironment  may  prevent 
initiation  of  antitumor  immune  responses  by  IFN-γ 
producing CD4+ Th1 cells and CD8+ T cells, but may 
not be sufficient to overcome the already established 
cycle  of  IL-6  and  STAT3-mediated  inflammation. 
There remains much to be learned of the interactions 
between  these  various  cell  types  within  the  tumor 
microenvironment.  However,  teasing  apart  and  un-
derstanding these mechanisms is essential to finding 
an  effective  therapeutic  approach  for  altering 
pro-tumor immune signaling while also limiting po-
tential side-effects for the patient. 
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